StockData
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. (TCRX) company profile

TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15+0.01 (+4.07%)

Close on Nov 17, 2026Market cap $10.23MP/E –Yield –

About TScan Therapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

The company is a clinical-stage biotechnology firm that develops T cell receptor-engineered T cell therapies to treat cancer and autoimmune conditions. Its primary clinical focus is on hematologic malignancies, led by candidate TSC-101 for patients with acute myeloid leukemia and myelodysplastic syndrome receiving allogeneic hematopoietic cell transplantation. The company is also developing candidates TSC-102-A01 and TSC-102-A03 targeting CD45, as well as preclinical in vivo multiplex therapies for solid tumors. In autoimmune indications, it discovers targets for conditions such as ankylosing spondylitis, ulcerative colitis, and Crohn's disease. Its potential end customers are patients suffering from these cancers and immune-mediated disorders.

The company operates an internal good manufacturing practices facility to produce clinical supply and collaborates with a global contract development and manufacturing organization with commercial capabilities. In addition, it conducts a multi-center clinical trial with more than 20 activated clinical sites across the United States. The provided text does not state the location of the company's corporate headquarters.

Summary of the business section of TScan Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
TScan Therapeutics, Inc.
Headquarters
Waltham, MA
Address
830 Winter Street 02451
Phone
(857) 399-9500
Website
tscan.com
Employees
142, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, Boston, Massachusetts

Stock & identifiers

Ticker
TCRX
Exchange
Nasdaq
IPO date
Jul 19, 2021
Shares outstanding
68M, Aug 7, 2026
Public float
$56.87M, Jun 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
1783328
CUSIP
89854M101
ISIN
US89854M1018
FIGI
BBG00PH1N007
Share class FIGI
BBG00PH1N025
EIN
82-5282075

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Gavin MacBeathChief Executive Officer, Director1,049,767
Zoran ZdraveskiSee Remarks304,716
Jason AmelloChief Financial Officer–
Chrystal LouisChief Medical Officer–
Leiden DworakSee Remarks5,692
Bros. Advisors (GP) LLC BakerDirector–
Keith WoodsDirector–
667, L.P.Director256,209
Katina DortonDirector–
Garry A. NicholsonDirector–
Gabriela GruiaDirector–
Barbara KlenckeDirector70,000
Bros. Advisors Lp BakerDirector–
Julian BakerDirector–
Felix BakerDirector–
Brothers Life Sciences LP BakerDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Gavin MacBeath, Ph.D.
Chief Executive Officer and Director
$665.00K$1.98M$139.65K$14.00K$2.80M+59%
Jason A. Amello
Chief Financial Officer and Treasurer (4)
$520.00K$669.20K$72.80K$14.00K$1.28M-66%
Chrystal Louis, M.D., M.P.H.
Chief Medical Officer (6)
$530.00K$991.40K$74.20K$14.00K$1.61M-47%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 19, 2021
Offer price
$15.00
Securities offered
6,666,667
Gross proceeds
$100.00M
Exchange
Nasdaq
First trading day
Jul 16, 2021
First-day close
$10.50-30.0%
Lock-up ends (est.)
Jan 12, 2022

“The initial public offering price is $15.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of February 27, 2026, we had 142 full-time employees and 0 part-time employees, 29 of whom have Ph.D.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?